FOXM1 expression further distinguishes meningiomas at risk for recurrence19, but the molecular mechanisms driving this process are poorly understood, and transcription factors, such as FOXM1, are not tractable pharmacologic targets. The gene discussed is FOXM1; the disease is meningioma.